DK4082530T3 - Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents
Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme Download PDFInfo
- Publication number
- DK4082530T3 DK4082530T3 DK22162188.1T DK22162188T DK4082530T3 DK 4082530 T3 DK4082530 T3 DK 4082530T3 DK 22162188 T DK22162188 T DK 22162188T DK 4082530 T3 DK4082530 T3 DK 4082530T3
- Authority
- DK
- Denmark
- Prior art keywords
- same
- preparing
- methods
- compositions
- protease inhibitors
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261632868P | 2012-02-01 | 2012-02-01 | |
| US201261634753P | 2012-03-06 | 2012-03-06 | |
| EP13744410.5A EP2814504B1 (en) | 2012-02-01 | 2013-01-31 | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4082530T3 true DK4082530T3 (da) | 2024-05-06 |
| DK4082530T5 DK4082530T5 (da) | 2024-07-22 |
Family
ID=48904507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22162188.1T DK4082530T5 (da) | 2012-02-01 | 2013-01-31 | Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme |
| DK13744410.5T DK2814504T3 (da) | 2012-02-01 | 2013-01-31 | Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13744410.5T DK2814504T3 (da) | 2012-02-01 | 2013-01-31 | Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10342764B2 (da) |
| EP (2) | EP2814504B1 (da) |
| JP (3) | JP6567827B2 (da) |
| CN (3) | CN112755002A (da) |
| DK (2) | DK4082530T5 (da) |
| ES (1) | ES2912138T3 (da) |
| HK (1) | HK1200727A1 (da) |
| HU (1) | HUE066433T2 (da) |
| WO (1) | WO2013114369A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228621A1 (en) | 2004-08-09 | 2018-08-16 | Mark A. Reiley | Apparatus, systems, and methods for the fixation or fusion of bone |
| US9259456B2 (en) * | 2005-09-06 | 2016-02-16 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| RU2504373C2 (ru) | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Способы и композиции для перорального введения протеинов |
| CN105903005A (zh) | 2008-05-05 | 2016-08-31 | 奥拉姆德有限公司 | 用于口服给予艾塞那肽的方法和组合物 |
| US10398762B2 (en) | 2012-01-03 | 2019-09-03 | Oramed Ltd. | Methods and compositions for treating diabetes |
| CN112755002A (zh) | 2012-02-01 | 2021-05-07 | 奥拉姆德有限公司 | 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法 |
| US9044321B2 (en) | 2012-03-09 | 2015-06-02 | Si-Bone Inc. | Integrated implant |
| US10363140B2 (en) | 2012-03-09 | 2019-07-30 | Si-Bone Inc. | Systems, device, and methods for joint fusion |
| WO2013166496A1 (en) | 2012-05-04 | 2013-11-07 | Si-Bone Inc. | Fenestrated implant |
| EP2941267B1 (en) | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions for use in treating nafld |
| WO2014145902A1 (en) | 2013-03-15 | 2014-09-18 | Si-Bone Inc. | Implants for spinal fixation or fusion |
| US11147688B2 (en) | 2013-10-15 | 2021-10-19 | Si-Bone Inc. | Implant placement |
| US10166033B2 (en) | 2014-09-18 | 2019-01-01 | Si-Bone Inc. | Implants for bone fixation or fusion |
| ES3030703T3 (en) | 2014-09-18 | 2025-07-01 | Si Bone Inc | Matrix implant |
| CN105343184A (zh) * | 2015-12-01 | 2016-02-24 | 无限极（中国）有限公司 | 一种组合物及其应用 |
| EP3429612A4 (en) * | 2016-03-16 | 2020-04-08 | AmideBio LLC | METHODS OF PRODUCING PEPTIDES AND USES THEREOF |
| EP3687422A4 (en) | 2017-09-26 | 2021-09-22 | SI-Bone, Inc. | SYSTEMS AND PROCESSES FOR DECORTICATION OF THE SACROILIAC JOINT |
| EP4516267A3 (en) | 2018-03-28 | 2025-05-21 | SI-Bone, Inc. | Threaded implants and methods of use across bone segments |
| MX2020013296A (es) * | 2018-06-11 | 2021-05-27 | Oramed Ltd | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. |
| US11369419B2 (en) | 2019-02-14 | 2022-06-28 | Si-Bone Inc. | Implants for spinal fixation and or fusion |
| ES3053909T3 (en) | 2019-02-14 | 2026-01-27 | Si Bone Inc | Implants for spinal fixation and or fusion |
| AU2020386985A1 (en) | 2019-11-21 | 2022-06-02 | Si-Bone Inc. | Rod coupling assemblies for bone stabilization constructs |
| ES3042147T3 (en) | 2019-11-27 | 2025-11-18 | Si Bone Inc | Bone stabilizing implants across si joints |
| WO2021119126A1 (en) | 2019-12-09 | 2021-06-17 | Si-Bone Inc. | Sacro-iliac joint stabilizing implants and methods of implantation |
| JP2023553120A (ja) | 2020-12-09 | 2023-12-20 | エスアイ－ボーン・インコーポレイテッド | 仙腸関節安定化インプラントおよびインプラント方法 |
| GB202019817D0 (en) * | 2020-12-15 | 2021-01-27 | Univ Oxford Innovation Ltd | Ligand-binding polypeptides and uses thereof |
| US20240366731A1 (en) * | 2021-08-12 | 2024-11-07 | Celagenex Research (India) Pvt. Ltd. | Oral algal oil based gastro-intestinal tract permeable peptide composition |
| WO2023102533A1 (en) | 2021-12-03 | 2023-06-08 | Si-Bone Inc. | Fusion cages and methods for sacro-iliac joint stabilization |
| CN117186237A (zh) * | 2022-05-29 | 2023-12-08 | 中国医学科学院药物研究所 | 一种含有糜蛋白酶抑制肽的胰岛素杂交肽及其应用 |
| WO2025038769A1 (en) | 2023-08-15 | 2025-02-20 | Si-Bone Inc. | Pelvic stabilization implants, methods of use and manufacture |
| WO2025152922A1 (zh) * | 2024-01-15 | 2025-07-24 | 合肥天汇生物科技有限公司 | 使用分离的bbi和kti的多肽组合物及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| JPS6350793A (ja) | 1986-08-20 | 1988-03-03 | 株式会社東芝 | 高速増殖炉の崩壊熱除去システム |
| US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
| EP0351651B1 (en) | 1988-07-21 | 1993-09-15 | F. Hoffmann-La Roche Ag | Insulin preparation |
| JPH02250823A (ja) | 1989-03-24 | 1990-10-08 | Tsumura & Co | マイクロカプセル剤およびその製造方法 |
| GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
| US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| JPH06145198A (ja) * | 1992-03-30 | 1994-05-24 | Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai | 大豆トリプシンインヒビターの製造方法 |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| IL114673A (en) | 1995-07-19 | 2000-12-06 | Hadasit Med Res Service | Pharmaceutical compositions containing protein for oral administration |
| JPH09208485A (ja) | 1996-01-31 | 1997-08-12 | Teijin Ltd | ペプチド・蛋白質性薬物の水難溶性組成物 |
| ES2359031T3 (es) | 1996-08-08 | 2011-05-17 | Amylin Pharmaceuticals, Inc. | Composición farmacéutica que comprende un péptido de exendina-4. |
| JPH10330287A (ja) | 1997-03-31 | 1998-12-15 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤 |
| JP2000128805A (ja) | 1998-10-27 | 2000-05-09 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤 |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| JP2001240558A (ja) | 2000-02-29 | 2001-09-04 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。 |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| KR20010069322A (ko) | 2001-03-08 | 2001-07-25 | 서종수 | 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법 |
| KR20010069433A (ko) | 2001-03-22 | 2001-07-25 | 김윤완 | 노루궁뎅이버섯을 이용한 건강 보조 식품 |
| CN1160122C (zh) * | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| AU2002316717B8 (en) | 2001-07-18 | 2005-09-29 | Solae Holdings Llc | High protein, Bowman-Birk Inhibitor Concentrate and process for its manufacture |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| JP4165329B2 (ja) * | 2002-07-31 | 2008-10-15 | 不二製油株式会社 | 大豆ホエー分画物の製造法 |
| US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20050143303A1 (en) | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| MXPA06011871A (es) | 2004-04-15 | 2007-10-08 | Chiasma Inc | Composiciones capaces de facilitar la penetracion a traves de una barrera biologica. |
| MX2007000883A (es) | 2004-07-19 | 2007-04-02 | Biocon Ltd | Conjugados de insulina-oligomero, formulaciones y usos de los mismos. |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2006025882A2 (en) | 2004-08-25 | 2006-03-09 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US20080274945A1 (en) | 2004-11-26 | 2008-11-06 | N.V. Nutricia | Infant Nutrition With Protease Inhibitor |
| US9259456B2 (en) | 2005-09-06 | 2016-02-16 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US20070086972A1 (en) | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
| US20070077283A1 (en) | 2005-09-30 | 2007-04-05 | Nastech Pharmaceutical Company Inc. | Method of enhancing transmucosal delivery of therapeutic compounds |
| CN101095942B (zh) | 2006-06-30 | 2011-11-16 | 北京民海生物科技有限公司 | 一种包含稳定剂的Exendin-4注射剂药物配方 |
| RU2504373C2 (ru) * | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Способы и композиции для перорального введения протеинов |
| CN105903005A (zh) | 2008-05-05 | 2016-08-31 | 奥拉姆德有限公司 | 用于口服给予艾塞那肽的方法和组合物 |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| CN102123697B (zh) | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| US20130023649A1 (en) * | 2009-12-30 | 2013-01-24 | Karsten Keller | Method for Recovering Kunitz-Trypsin Inhibitor Proteins from a Soy Processing Stream |
| US10398762B2 (en) * | 2012-01-03 | 2019-09-03 | Oramed Ltd. | Methods and compositions for treating diabetes |
| CN112755002A (zh) | 2012-02-01 | 2021-05-07 | 奥拉姆德有限公司 | 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法 |
| EP2941267B1 (en) | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions for use in treating nafld |
| MX2020013296A (es) | 2018-06-11 | 2021-05-27 | Oramed Ltd | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. |
-
2013
- 2013-01-31 CN CN202011450718.2A patent/CN112755002A/zh active Pending
- 2013-01-31 DK DK22162188.1T patent/DK4082530T5/da active
- 2013-01-31 HU HUE22162188A patent/HUE066433T2/hu unknown
- 2013-01-31 EP EP13744410.5A patent/EP2814504B1/en active Active
- 2013-01-31 DK DK13744410.5T patent/DK2814504T3/da active
- 2013-01-31 EP EP22162188.1A patent/EP4082530B1/en active Active
- 2013-01-31 WO PCT/IL2013/050091 patent/WO2013114369A1/en not_active Ceased
- 2013-01-31 ES ES13744410T patent/ES2912138T3/es active Active
- 2013-01-31 JP JP2014555388A patent/JP6567827B2/ja active Active
- 2013-01-31 US US14/376,292 patent/US10342764B2/en active Active
- 2013-01-31 CN CN202110986054.XA patent/CN113769074A/zh active Pending
- 2013-01-31 CN CN201380018355.7A patent/CN104244969A/zh active Pending
- 2013-01-31 HK HK15101307.9A patent/HK1200727A1/xx unknown
-
2018
- 2018-01-30 JP JP2018014208A patent/JP7064226B2/ja active Active
-
2019
- 2019-05-09 US US16/407,737 patent/US10933022B2/en active Active
-
2020
- 2020-03-31 JP JP2020063443A patent/JP2020117518A/ja active Pending
-
2021
- 2021-02-01 US US17/164,039 patent/US20210369626A1/en not_active Abandoned
-
2023
- 2023-12-22 US US18/394,246 patent/US20240358647A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104244969A (zh) | 2014-12-24 |
| US20210369626A1 (en) | 2021-12-02 |
| ES2912138T3 (es) | 2022-05-24 |
| JP2018104443A (ja) | 2018-07-05 |
| EP4082530B1 (en) | 2024-04-10 |
| CN112755002A (zh) | 2021-05-07 |
| US10342764B2 (en) | 2019-07-09 |
| JP2015510506A (ja) | 2015-04-09 |
| EP2814504A4 (en) | 2015-10-14 |
| WO2013114369A1 (en) | 2013-08-08 |
| EP2814504A1 (en) | 2014-12-24 |
| JP2020117518A (ja) | 2020-08-06 |
| JP7064226B2 (ja) | 2022-05-10 |
| EP2814504B1 (en) | 2022-03-16 |
| CN113769074A (zh) | 2021-12-10 |
| EP4082530A1 (en) | 2022-11-02 |
| US10933022B2 (en) | 2021-03-02 |
| HK1200727A1 (en) | 2015-08-14 |
| HUE066433T2 (hu) | 2024-08-28 |
| JP6567827B2 (ja) | 2019-08-28 |
| US20240358647A1 (en) | 2024-10-31 |
| DK4082530T5 (da) | 2024-07-22 |
| US20190321303A1 (en) | 2019-10-24 |
| US20140377344A1 (en) | 2014-12-25 |
| DK2814504T3 (da) | 2022-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4082530T3 (da) | Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK2884999T4 (da) | Fremgangsmåde og sammensætninger til cellulær immunterapi | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3027186T3 (da) | Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid | |
| DK3386534T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK2800565T3 (da) | Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK2811876T4 (da) | Kaffemaskine og fremgangsmåde til betjening af samme | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3628161T3 (da) | Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
| DK2885261T3 (da) | Flydende sammensætninger, der indeholder ureaseinhibitorer og glycolalkylethere | |
| DK2914741T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| DK3594348T3 (da) | Kort c/ebp-alpha til aktivering af rna-sammensætninger og anvendelsesfremgangsmåder | |
| DK2970890T3 (da) | Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller | |
| DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
| DK2928495T3 (da) | Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme |